Zacks: Brokerages Anticipate AC Immune SA (ACIU) Will Announce Quarterly Sales of $4.75 Million

Wall Street analysts expect AC Immune SA (NASDAQ:ACIU) to report $4.75 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for AC Immune’s earnings. The lowest sales estimate is $2.90 million and the highest is $6.59 million. AC Immune reported sales of $16.64 million during the same quarter last year, which indicates a negative year-over-year growth rate of 71.5%. The firm is expected to report its next quarterly earnings results on Tuesday, March 19th.

On average, analysts expect that AC Immune will report full-year sales of $8.20 million for the current fiscal year, with estimates ranging from $3.51 million to $12.39 million. For the next fiscal year, analysts forecast that the company will report sales of $13.11 million, with estimates ranging from $6.99 million to $19.22 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow AC Immune.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Tuesday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.04. AC Immune had a negative return on equity of 24.14% and a negative net margin of 146.09%. The business had revenue of $2.34 million during the quarter, compared to analyst estimates of $1.71 million.

A number of brokerages have issued reports on ACIU. Zacks Investment Research upgraded AC Immune from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Wednesday, November 21st. BidaskClub upgraded AC Immune from a “hold” rating to a “buy” rating in a research note on Wednesday, November 21st. HC Wainwright set a $18.00 price target on AC Immune and gave the stock a “buy” rating in a research note on Thursday, August 9th. ValuEngine lowered AC Immune from a “buy” rating to a “hold” rating in a research note on Monday, August 20th. Finally, Leerink Swann began coverage on AC Immune in a research note on Monday, November 12th. They issued an “outperform” rating and a $18.00 price target for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. AC Immune presently has a consensus rating of “Buy” and an average price target of $15.25.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in shares of AC Immune by 28.9% during the 3rd quarter. FMR LLC now owns 5,209,673 shares of the company’s stock valued at $41,678,000 after purchasing an additional 1,166,524 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of AC Immune during the 3rd quarter valued at about $13,345,000. Artal Group S.A. boosted its holdings in shares of AC Immune by 25.0% during the 3rd quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock valued at $6,000,000 after purchasing an additional 150,000 shares during the last quarter. Sphera Funds Management LTD. bought a new position in shares of AC Immune during the 3rd quarter valued at about $4,029,000. Finally, Citadel Advisors LLC bought a new position in shares of AC Immune during the 3rd quarter valued at about $2,279,000. 29.06% of the stock is owned by institutional investors and hedge funds.

ACIU stock traded up $0.47 during trading on Friday, reaching $11.13. The company’s stock had a trading volume of 7,745 shares, compared to its average volume of 81,587. AC Immune has a 1 year low of $7.16 and a 1 year high of $17.40. The firm has a market capitalization of $718.56 million, a PE ratio of -36.10 and a beta of 1.27.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Article: How to calculate compound interest

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AC Immune (NASDAQ:ACIU)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply